We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 85

Range in dosage regimen claims found not to invoke physician’s judgement
  • Bereskin & Parr LLP
  • Canada
  • April 17 2017

There has been a significant amount of uncertainty in Canada regarding the patentability of use claims which include dosages and dosage regimens


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Tribunal Decides in Favour of Canada in NAFTA Arbitration Suit
  • Bereskin & Parr LLP
  • Canada
  • March 21 2017

The Government of Canada has prevailed in its NAFTA arbitration suit with Eli Lilly and Company “Lilly”. Lilly sued the sued the government as a


Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian


Patenting Polymorphs of Crystals Internationally
  • Bereskin & Parr LLP
  • Canada, European Union, Japan, USA
  • June 27 2016

Polymorphs are patentable subject matter in Canada and the U.S. Our prior article discussed some best practices to differentiate a new polymorph from


CIPO updates guidance on medical use claims
  • Bereskin & Parr LLP
  • Canada
  • March 23 2015

On March 18, 2015 the Canadian Intellectual Property Office issued a practice notice containing revised examination practice guidelines pertaining to


Expert opinion as to what “one would expect” is speculation, not evidence
  • Bereskin & Parr LLP
  • Canada
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice


Biosimilar battlegrounds - what is new in biosimilars and where?
  • Bereskin & Parr LLP
  • Canada, European Union, USA
  • February 17 2012

Biosimilars are second entry biologic drugs


The Requirement of Causation in an Accounting of Profits - Federal Court of Appeal rules on Availability of Non-Infringing Alternatives and Apportionment of Non-Infringing Services
  • Bereskin & Parr LLP
  • Canada
  • March 16 2017

In a recent patent Accounting of profits decision of the Federal Court of Appeal in Apotex Inc v ADIR, 2017 FCA 23, the Court emphasized that the


Supreme Court Promises to Review Contentious Patent Matter
  • Bereskin & Parr LLP
  • Canada
  • March 14 2016

At long last, the Supreme Court of Canada will hear a case involving the promise of the patent. The promise of the patent is a judge-made doctrine in